Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.
A novel α/β T-cell clone with broad reactivity against human clear cell renal cell carcinomas (RCC) was generated from a patient with renal cancer. The T-cell receptor (TCR) from this clone recognizes soluble TNF-related apoptosis inducing ligand bound to death receptor 4, a complex found on the surface of nearly all RCC. In this study, we modified this novel TCR by introducing amino acid (AA) substitutions in its complementarity determining region 2 (CDR2) and CDR3 regions of both chains, to increase its activity. We demonstrated that tumor recognition by PBL, retrovirally-transduced with these TCRs, was decreased or unchanged by substitutions in the TCR beta chain, and in the CDR2α region. Yet some AA substitutions in the CDR3α region at positions 109 and 112 could augment tumor recognition. Specifically, substituting phenylalanine for tyrosine at AA109 (109Y-F) and alanine or lysine for serine at AA112 (112S-K or 112 S-A) augmented tumor recognition. Increased benefit was seen on combining both AA substitutions and a retrovirus encoding the modified TCR 109Y-F/112S-K conferred the best tumor recognition to transduced PBL. This modified TCR retained the recognition pattern of parental clone HC/2G-1 against RCC lines, other tumors and normal tissues. These results document that CDR3α plays an important role in the interaction of the HC/2G-1 TCR and its novel ligand. A phase I/II clinical trial, adoptively transferring autologous PBL transduced with this modified TCR has just begun in patients with metastatic RCC.
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. qiongwang@mail.nih.gov
Qiong J
QJ
Wang
Ken-ichi
K
Hanada
Steven A
SA
Feldman
Yangbing
Y
Zhao
Takashi
T
Inozume
James C
JC
Yang
D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D001483:Base Sequence; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000628:therapy*; D045744:Cell Line, Tumor; D022801:Complementarity Determining Regions; D017931:DNA Primers / Q000235:genetics; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007680:Kidney Neoplasms / Q000276:immunology* / Q000628:therapy*; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000737:chemistry / Q000235:genetics* / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology*; D014161:Transduction, Genetic
D022801:Complementarity Determining Regions; D017931:DNA Primers; D016693:Receptors, Antigen, T-Cell, alpha-beta; D011994:Recombinant Proteins
J Immunol. 1999 Jul 1;163(1):483-90
10384152
Cancer Res. 2001 Jul 15;61(14):5511-6
11454700
J Immunol. 1999 Feb 1;162(3):1730-8
9973436
Cancer Res. 1999 Nov 1;59(21):5554-9
10554034
Hum Gene Ther. 2005 Apr;16(4):457-72
15871677
Clin Immunol. 2006 May;119(2):135-45
16458072
Annu Rev Immunol. 2008;26:171-203
18304006
J Clin Oncol. 2008 Nov 10;26(32):5233-9
18809613
Cancer Res. 1998 Dec 15;58(24):5803-11
9865739
J Immunol. 2008 May 1;180(9):6116-31
18424733
Immunity. 2005 Jan;22(1):117-29
15664164
J Exp Med. 2009 Feb 16;206(2):463-75
19171765
J Immunother. 2005 Nov-Dec;28(6):551-9
16224272
Nat Biotechnol. 2004 May;22(5):589-94
15064769
Science. 2002 Oct 25;298(5594):850-4
12242449
J Clin Oncol. 2005 Apr 1;23(10):2346-57
15800326
Cancer Res. 2007 Apr 15;67(8):3898-903
17440104
J Immunol. 2005 Apr 1;174(7):4415-23
15778407
Immunity. 1998 Apr;8(4):413-25
9586632
J Immunol. 2008 Sep 15;181(6):3769-76
18768829
Cancer Res. 1998 Feb 15;58(4):732-6
9485028
Blood. 2009 Jul 16;114(3):535-46
19451549
Science. 2006 Oct 6;314(5796):126-9
16946036
J Clin Oncol. 2003 Aug 15;21(16):3127-32
12915604